Flanvotumab
From Wikipedia, the free encyclopedia
Monoclonal antibody
Pharmaceutical compound
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | HGF |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6470H9986N1714O2018S46 |
| Molar mass | 145545.80 g·mol−1 |
 N Y (what is this?) (verify) | |
Flanvotumab, also known as IMC-20D7S, is a human monoclonal antibody designed for the treatment of melanoma.[1] It targets TYRP1.[2]
Flanvotumab was developed by ImClone Systems, now owned by Eli Lilly.[2] It was discontinued in 2012.[3]
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Flanvotumab" (PDF). American Medical Association.
- 1 2 "Flanvotumab". Adis Insight. Springer Nature Switzerland AG.
- ↑ Williams R (December 2013). "Discontinued drugs in 2012: oncology drugs". Expert Opinion on Investigational Drugs. 22 (12): 1627–1644. doi:10.1517/13543784.2013.847088. PMID 24102323.
| Angiopoietin |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CNTF |
| ||||||||||
| EGF (ErbB) |
| ||||||||||
| FGF |
| ||||||||||
| HGF (c-Met) |
| ||||||||||
| IGF |
| ||||||||||
| LNGF (p75NTR) |
| ||||||||||
| PDGF |
| ||||||||||
| RET (GFL) |
| ||||||||||
| SCF (c-Kit) |
| ||||||||||
| TGFβ |
| ||||||||||
| Trk |
| ||||||||||
| VEGF |
| ||||||||||
| Others |
| ||||||||||
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |